The endogenous bioactive lipid prostaglandin D 2 ‐glycerol ester reduces murine colitis via DP1 and PPARγ receptors

What is it about?

Inflammatory bowel diseases are chronic relapsing-remitting disorders of the gastrointestinal tract that have a significant impact on quality of life of the patients. Current treatment strategies lose their efficacy over time or have significant side effects, thus the need for new therapeutic avenues. In this context, bioactive lipids are more and more implicated in the inflammatory process, from initiation to resolution. The aim of our study was to evaluate the effect of prostaglandin-D2-glycerol ester (PGD2-G), an anti-inflammatory bioactive lipid, in colon inflammation using mouse models. Our work suggests a decrease in the levels of this bioactive lipid during colitis. In accordance with its anti-inflammatory properties, administration of PGD2-G reduces the main markers of colon inflammation. No targets have been described for this lipid to date. In trying to understand the mechanisms by which PGD2-G decreased colon inflammation, we found that it binds to the DP1 receptor. Moreover, the effects of PGD2-G were also dependent on the PPARɣ receptor, probably through one of its metabolites. In conclusion, our work puts forth a role for PGD2-G in colon inflammation.

Featured Image